For example, three oral small molecule c-MET TKIs have demonstrated acceptable toxicity and modest clinical efficacy in Phase II trials in advanced HCC: foretinib [30], cabozantinib [31], and tivantinib [32]. The gene discussed is MET; the disease is hepatocellular carcinoma.